medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2023, Number 3

<< Back Next >>

Rev Nefrol Dial Traspl 2023; 43 (3)

Long-term Effects of Gastric Acid Prophylaxis in Kidney Transplant Recipients

Yazici H, Akin OO, Mirioglu S, Burak DA, Demir E, Uludag O, Faruk AO, Caliskan Y, Lentine KL

Language: English
References: 25
Page: 156-166
PDF size: 418.32 Kb.


ABSTRACT

Objectives: Prophylactic acid suppression with proton pump inhibitors or H2 receptor antagonists is often administered after kidney transplantation. The association of proton pump inhibitors or H2 receptor antagonists with acute rejection, hypomagnesemia, and graft loss in kidney transplant recipients is not well established. Materials and Methods: We performed a retrospective cohort study of 302 kidney transplant recipients at one center (57% male; mean age 35.5±11.2 years) with more than six months post-transplant follow-up. Recipients were grouped according to gastric acid prophylaxis: only proton pump inhibitors (n=179), only H2 receptor antagonists (n=42), proton pump inhibitors and H2 receptor antagonists (n=55), and nonusers (n=26). The primary outcome was biopsy-proven acute rejection. Graft loss and hypomagnesemia were defined as secondary outcomes. Results: Nonusers were younger and mostly under steroid-free immunosuppression compared to other study groups (p = 0.030 and p = 0.009, respectively). The primary outcome was similar across study groups (p = 0.266). Kaplan-Meier analyses also demonstrated similar 10-year graft survival rates: 95.5% for proton pump inhibitors, 97.6% for H2 receptor antagonists, 100% for proton pump inhibitors/ H2 receptor antagonists, and 96.2% for nonusers (p = 0.275). Conclusions: Using proton pump inhibitors is not associated with acute rejection or graft loss but may cause mild hypomagnesemia in kidney transplant recipients.


REFERENCES

  1. Hess M, Hoenderop J, Bindels R, Drenth J. Systematicreview: hypomagnesemia induced by proton pumpinhibition. Alimentary pharmacology & therapeutics. 2012;36(5):405-413.

  2. Cheungpasitporn W, Thongprayoon C,Kittanamongkolchai W, et al. Proton pump inhibitorslinked to hypomagnesemia: a systematic review andmeta-analysis of observational studies. Renal failure.2015;37(7):1237-1241.

  3. Hoorn EJ, van der Hoek J, Rob A, Kuipers EJ,Bolwerk C, Zietse R. A case series of proton pumpinhibitor–induced hypomagnesemia. Americanjournal of kidney diseases. 2010;56(1):112-116.

  4. Cundy T, Dissanayake A. Severe hypomagnesemia inlong‐term users of proton‐pump inhibitors. Clinicalendocrinology. 2008;69(2):338-341.

  5. Van Ende C, Van Laecke S, Marechal C, et al. Protonpumpinhibitors do not influence serum magnesiumlevels in renal transplant recipients. Journal ofNephrology. 2014;27(6):707-711.

  6. Markovits N, Loebstein R, Halkin H, et al.The association of proton pump inhibitors andhypomagnesemia in the community setting. TheJournal of Clinical Pharmacology. 2014;54(8):889-895.

  7. Joosten MM, Gansevoort RT, Mukamal KJ, et al.Urinary magnesium excretion and risk of hypertension:the prevention of renal and vascular end-stage diseasestudy. Hypertension. 2013;61(6):1161-1167.

  8. Van Laecke S, Van Biesen W, Verbeke F, De BacquerD, Peeters P, Vanholder R. Posttransplantationhypomagnesemia and its relation withimmunosuppression as predictors of new‐onsetdiabetes after transplantation. American Journal ofTransplantation. 2009;9(9):2140-2149.

  9. Schaier M, Scholl C, Scharpf D, et al. Proton pumpinhibitors interfere with the immunosuppressivepotency of mycophenolate mofetil. Rheumatology.2010;49(11):2061-2067.

  10. Van Gelder T, Hilbrands L, Vanrenterghem Y,et al. A randomized, double-blind, multicenterplasma concentration-controlled study of thesafety and efficacy of oral mycophenolate mofetilfor the prevention of acute rejection after kidneytransplantation1. Transplantation. 1999;68(2):261-266.

  11. 11.te rejectionbenefit from adequate exposure to mycophenolicacid. Transplantation. 2010;89(5):595-599.

  12. Boonpheng B, Thongprayoon C, Bathini T, SharmaK, Mao MA, Cheungpasitporn W. Proton pumpinhibitors and adverse effects in kidney transplantrecipients: A meta-analysis. World journal oftransplantation. 2019;9(2):35.

  13. Levey AS, Stevens LA, Schmid CH, et al. A newequation to estimate glomerular filtration rate.Annals of internal medicine. 2009;150(9):604-612.

  14. Courson AY, Lee JR, Aull MJ, Lee JH, Kapur S,McDermott JK. Routine prophylaxis with protonpump inhibitors and post‐transplant complicationsin kidney transplant recipients undergoing earlycorticosteroid withdrawal. Clinical Transplantation.2016;30(6):694-702.

  15. Knorr JP, Sjeime M, Braitman LE, Jawa P, Zaki R,Ortiz J. Concomitant proton pump inhibitors withmycophenolate mofetil and the risk of rejectionin kidney transplant recipients. Transplantation.2014;97(5):518-524.

  16. Van Boekel GA, Kerkhofs CH, van de Logt F,Hilbrands LB. Proton pump inhibitors do notincrease the risk of acute rejection. The Netherlandsjournal of medicine. Feb 2014;72(2):86-90.

  17. Rouse GE, Hardinger K, Tsapepas D, Tichy EM.A comparison of histamine receptor antagonistsversus proton pump inhibitor gastrointestinal ulcerprophylaxis in kidney transplant recipients. Progressin Transplantation. 2017;27(1):4-9.

  18. Cooper M, Deering KL, Slakey DP, et al. Comparingoutcomes associated with dose manipulationsof enteric-coated mycophenolate sodium versusmycophenolate mofetil in renal transplant recipients.Transplantation. Aug 27, 2009;88(4):514-20.doi:10.1097/TP.0b013e3181b0e65e

  19. Langone A, Doria C, Greenstein S, et al. Doesreduction in mycophenolic acid dose compromiseefficacy regardless of tacrolimus exposure level? Ananalysis of prospective data from the M mycophenolicR enal T transplant (MORE) R registry. Clinicaltransplantation. 2013;27(1):15-24.

  20. Kees MG, Steinke T, Moritz S, et al. Omeprazoleimpairs the absorption of mycophenolate mofetilbut not of enteric‐coated mycophenolate sodiumin healthy volunteers. The Journal of ClinicalPharmacology. 2012;52(8):1265-1272.

  21. Miner Jr P, Katz PO, Chen Y, Sostek M. Gastric acidcontrol with esomeprazole, lansoprazole, omeprazole,pantoprazole, and rabeprazole: a five-way crossoverstudy. The American journal of gastroenterology.2003;98(12):2616-2620.

  22. Lachman L, Howden CW. Twenty-four-hourintragastric pH: tolerance within five days ofcontinuous ranitidine administration. The Americanjournal of gastroenterology. 2000;95(1):57-61.

  23. Prichard P, Jones D, Yeomans N, Mihaly G,Smallwood R, Louis W. The effectiveness ofranitidine in reducing gastric acid secretion decreaseswith continued therapy. British journal of clinicalpharmacology. 1986;22(6):663-668.

  24. Flothow DJG, Suwelack B, Pavenstädt H, Schütte-Nütgen K, Reuter S. The Effect of Proton PumpInhibitor Use on Renal Function in KidneyTransplanted Patients. J Clin Med. Jan 18, 2020;9(1)doi:10.3390/jcm9010258

  25. Douwes RM, Gomes-Neto AW, Schutten JC, et al.




2020     |     www.medigraphic.com